[go: up one dir, main page]

Lycopene inhibits hepatic steatosis via microRNA-21-induced downregulation of fatty acid-binding protein 7 in mice fed a high-fat diet

Mol Nutr Food Res. 2012 Nov;56(11):1665-74. doi: 10.1002/mnfr.201200182. Epub 2012 Sep 12.

Abstract

Scope: Nonalcoholic fatty liver disease (NAFLD) is a chronic disorder characterized by hepatic fat accumulation and abnormal lipid metabolism. Here, we investigated the protective effect of lycopene on high-fat diet-induced hepatic steatosis and fatty acid-induced intracellular lipid accumulation by miRNA regulation.

Methods and results: C57BL/6J mice were fed high-fat diet with or without 0.05% lycopene for 8 weeks. Hepa 1-6 cells were treated with stearic acid (SA) after 24 h pretreatment with lycopene. Treatment of lycopene improved hepatic steatosis in high-fat-fed mice and reduced intracellular lipid accumulation induced by SA in Hepa 1-6 cells. We demonstrated that miR-21 expression was decreased in livers from high-fat diet-fed mice and Hepa 1-6 cells treated with SA. Lycopene normalized the downregulation of miR-21, which led to the downregulation of fatty acid-binding protein 7 (FABP7), a direct target of miR-21, at both the transcriptional and translational levels. This specific negative regulation of miR-21 was achieved by targeting the FABP7 3'UTR. Upregulation of miR-21 markedly blocked SA-induced intracellular lipid accumulation by blocking FABP7 expression. Moreover, silencing of FABP7 reduced SA-evoked lipid accumulation in Hepa 1-6 cells.

Conclusion: The results suggest that lycopene may be a useful functional compound for treating NAFLD by regulating hepatic lipid metabolism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Carotenoids / pharmacology*
  • Cells, Cultured
  • Diet, High-Fat / adverse effects
  • Down-Regulation
  • Fatty Acid-Binding Protein 7
  • Fatty Acid-Binding Proteins / genetics
  • Fatty Acid-Binding Proteins / metabolism
  • Fatty Liver / genetics*
  • Fatty Liver / metabolism
  • Fatty Liver / prevention & control*
  • Gene Expression Regulation / drug effects
  • Lipid Metabolism / drug effects
  • Lycopene
  • Male
  • Mice
  • Mice, Inbred C57BL
  • MicroRNAs / genetics*
  • Nerve Tissue Proteins / genetics
  • Nerve Tissue Proteins / metabolism
  • Non-alcoholic Fatty Liver Disease
  • Stearic Acids / pharmacology

Substances

  • Fabp7 protein, mouse
  • Fatty Acid-Binding Protein 7
  • Fatty Acid-Binding Proteins
  • MIRN21 microRNA, mouse
  • MicroRNAs
  • Nerve Tissue Proteins
  • Stearic Acids
  • Carotenoids
  • stearic acid
  • Lycopene